FDA approves new cancer treatments amid concerns over infectious disease trends
美國食品藥物管理局在傳染病趨勢令人擔憂的情況下批准了新的癌症治療方法
更新於: 2026年9月24日 上午04:45
The year 2026 has marked an extraordinary period of medical advancement, with the FDA overseeing a rapid succession of pharmaceutical breakthroughs.
2026年是醫學進步非凡的一年，FDA監督了一系列藥物突破的快速發展。
Notable approvals include Tudriqev, a groundbreaking oncolytic viral therapy for melanoma, and Rasonque, the first oral inhibitor for pancreatic cancer.
值得注意的核准藥物包括Tudriqev，這是一種用於黑色素瘤的開創性溶瘤病毒療法，以及Rasonque，這是首款用於胰臟癌的口服抑制劑。
Additionally, treatments like Zenbexus, Inluriyo, and Hyrnuo have expanded options for myeloma, breast cancer, and lung cancer, respectively.
此外，Zenbexus、Inluriyo和Hyrnuo等治療藥物，也分別擴大了多發性骨髓瘤、乳癌和肺癌的治療選擇。
New HIV treatments, such as Bixlenvo and Idvynso, have been introduced, demonstrating ongoing innovation in virology.
Bixlenvo和Idvynso等新的HIV治療藥物已獲引進，顯示了病毒學領域持續的創新。
Of particular interest to researchers is the intersection of these fields, especially through oncolytic viral therapies that leverage engineered viruses to target cancer cells.
研究人員特別感興趣的是這些領域的交叉點，特別是透過利用工程病毒標靶癌細胞的溶瘤病毒療法。
Ultimately, this busy season of FDA activity reflects a transformative time in medicine, where innovation in precision oncology and viral treatments is moving faster than ever to address some of humanity's most complex health challenges.
總而言之，FDA這段繁忙的審核期反映了醫學變革的時代，精準腫瘤學與病毒治療的創新正以前所未有的速度發展，以應對人類一些最複雜的健康挑戰。
